European Journal of Integrative Medicine最新文献

{"title":"Acupuncture for Parkinson's disease-related constipation: A systematic review and meta-analysis","authors":"Xin-Xin Feng ,&nbsp;Lei Chen ,&nbsp;Yong-Yi Xu ,&nbsp;Kai Zhou ,&nbsp;Kai-Yu Huang","doi":"10.1016/j.eujim.2024.102332","DOIUrl":"10.1016/j.eujim.2024.102332","url":null,"abstract":"<div><h3>Introduction</h3><p>The hazard of Parkinson's disease-related constipation (PDC) cannot be ignored. Acupuncture has the potential to become a mainstream treatment option for PDC. This review aimed to investigate the effect of acupuncture on PDC, which might provide evidence-based recommendations for clinical application.</p></div><div><h3>Methods</h3><p>Six databases were searched for randomized controlled trials (RCTs) about acupuncture for PDC. The primary outcome was response rate. The secondary outcomes were rectal resting pressure, anal resting pressure, anal maximum contraction pressure, rectal sensation threshold, rectal maximum tolerable volume, the Constipation Scoring System (CSS) score, the Patient Assessment of Constipation Quality of Life (PAC-QOL) score, and adverse events (AEs).</p></div><div><h3>Results</h3><p>Eight trials involving 591 participants were included. The methodological quality was generally low. A significant difference was found in response rate when comparing acupuncture with medicine (95 %CI= 1.09 to 1.54, <em>P</em> = 0.003) or blank control (95 %CI= 1.04 to 1.74, <em>P</em> = 0.02), while no significant difference was observed when comparing acupuncture + medicine with medicine. Acupuncture + medicine did have a significant effect on rectal resting pressure, anal resting pressure, anal maximum contraction pressure, rectal sensation threshold and rectal maximum tolerable volume when compared with medicine, while no significant effect was found when acupuncture was compared with medicine. A significant difference was found in the CSS score when acupuncture was compared with blank and in the PAC-QOL score when acupuncture was compared with sham or blank, while no significant difference was found in the PAC-QOL score when acupuncture was compared with medicine. One study reported mild AEs.</p></div><div><h3>Conclusions</h3><p>Acupuncture might be an effective treatment for PDC. Due to the limited quality of evidence, high-caliber and multi-center RCTs with large sample sizes should be carried out.</p><p>(PROSPERO ID is CRD42023422102)</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"65 ","pages":"Article 102332"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139375274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese herbal medicine Er-xian decoction for primary ovarian insufficiency: A systematic review of randomized controlled trials and meta-analyses","authors":"Zhefen Mai ,&nbsp;Chunli Lu ,&nbsp;Xinyan Jin ,&nbsp;Zixun Zhuang ,&nbsp;Lingjing Lu ,&nbsp;Yu Su ,&nbsp;Chun Luo ,&nbsp;Xia Han ,&nbsp;Shaochuan Huo ,&nbsp;Hongxia Ma","doi":"10.1016/j.eujim.2024.102333","DOIUrl":"10.1016/j.eujim.2024.102333","url":null,"abstract":"<div><h3>Introduction</h3><p>The limitations of hormone therapy for managing primary ovarian insufficiency (POI) have prompted trialists to evaluate the Chinese herbal medicine, Er-xian decoction (containing <em>Curculiginis Rhizome, Epimrdii Herba, Angelicae Sinensis Radix, Morindae Officinalis Radix, Phellodendri Chinrnsis Cortex</em> and <em>Anemarrhenae Rhizoma</em>) for treating POI. This review was conducted to evaluate the effectiveness and safety of Er-xian decoction alone or in addition to hormone therapy in treating POI.</p></div><div><h3>Methods</h3><p>We conducted a systematic review of randomized controlled trials (RCTs) that reported on Er-xian decoction alone or in addition to hormone therapy in women with POI. Seven databases were searched from inception to 7 June 2023. The included studies were screened with Endnote X9, and methodological quality was assessed using the Cochrane “Risk of bias” tool v1.0. Effects were calculated as mean difference (MD), standard mean difference (SMD), or relative risk with 95% confidence interval (CI) using Review Manager 5.4.1, and data not suitable for statistical analyses were assessed by qualitative methods.</p></div><div><h3>Results</h3><p>Fifteen studies involving 1274 participants (13 drop-outs) were included. Er-xian decoction plus hormone therapy significantly lowered the follicle-stimulating hormone level (MD –12.48, 95 %CI –15.90 to –9.06; <em>N</em> = 8; <em>P</em> &lt; 0.001) and luteinizing hormone level (MD –8.20, 95 %CI –11.22 to –5.17; <em>N</em> = 8; <em>P</em> &lt; 0.001) and increased the estrogen level (SMD 2.35, 95 %CI 1.52 to 3.18; <em>N</em> = 8; <em>P</em> &lt; 0.001) compared with hormone therapy. There was no significant difference between Er-xian decoction alone and hormone therapy alone in terms of follicle-stimulating hormone level (MD –0.69; 95 %CI, –7.94 to 6.56; <em>N</em> = 5; <em>P</em> = 0.85), luteinizing hormone level (MD 0.29, 95 %CI –3.96 to 4.54; <em>N</em> = 5; <em>P</em> = 0.89) or estrogen level (SMD 0.16, 95 %CI –0.36 to 0.67; <em>N</em> = 5; <em>P</em> = 0.55). In addition, both Er-xian decoction alone and Er-xian decoction plus hormone therapy effectively improved women's menopausal symptoms. Seven studies reported on the occurrence of adverse events, and no severe events were reported.</p></div><div><h3>Conclusion</h3><p>The findings suggest Er-xian decoction, with or without hormone therapy, may be an effective treatment for POI. However, limitations in the evidence included a high risk of bias and substantial heterogeneity. Further research should be conducted in well-designed and rigorously executed clinical trials with large samples.</p></div><div><h3>Review registration</h3><p>INPLASY 2,021,110,107.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"65 ","pages":"Article 102333"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139375390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the effects of Bauhinia forficata as an adjuvant in the treatment of type 2 diabetes mellitus: Systematic review and meta-analysis","authors":"Liliana Maria Dimer ,&nbsp;Tamy Colonetti ,&nbsp;Maria Laura Rodrigues Uggioni ,&nbsp;Sarah Dagostin Ferraz ,&nbsp;Antonio José Grande ,&nbsp;Maria Inês Rosa ,&nbsp;Luciane Bisognin Ceretta","doi":"10.1016/j.eujim.2024.102331","DOIUrl":"10.1016/j.eujim.2024.102331","url":null,"abstract":"<div><h3>Introduction</h3><p>Type 2 diabetes mellitus (T2DM) is characterized by defects in insulin action and secretion. <em>Bauhinia forficata</em> has been observed to exhibit an effect in diabetes treatment due to its hypoglycemic activity. This systematic review with meta-analysis aimed to assess the effects of using <em>Bauhinia forficata</em> as an adjuvant treatment for individuals with T2DM.</p></div><div><h3>Methods</h3><p>We conducted a comprehensive search strategy using relevant keywords and their synonyms, focusing on \"<em>Bauhinia forficata</em>\" and \"diabetes mellitus.\" The search encompassed online databases such as Medline, Embase via OVID, and the Cochrane Library, without imposing language restrictions. We included studies that evaluated individuals diagnosed with T2DM, who were administered <em>Bauhinia forficata,</em> compared to placebo or active control, and who presented glycemia and glycated hemoglobin as outcome measures. Studies not meeting these criteria, as well as literature reviews, animal or in vitro experiments, were excluded. The methodological quality of the included studies was assessed using the Risk of Bias 2 tool. The results were presented through tables and graphs, and forest plots were generated to illustrate the effects of interventions on various outcomes, using RevMan software 5.4.</p></div><div><h3>Results</h3><p>Four studies met the inclusion criteria, comprising two randomized controlled trials (RCT) and two non-randomized studies of interventions (NRSI). Compared to placebo, <em>Bauhinia forficata</em> significantly improved glycemia (SMD -0.60, 95 % CI -0.15 to -1.05, <em>p</em> = 0.009, 1 RCT, <em>n</em> = 111, low certainty evidence; SMD -0.64, 95 % CI -1.25 to -0.03, <em>p</em> = 0.04, I²=42 %, 2 NSRIs pre-test/post-test, <em>n</em> = 40, very low certainty evidence). However, only the RCT evidence demonstrated significant improvements in HbA1c (SMD -0.48, 95 % CI -0.93, <em>p</em> = 0.03, 1 RCT, <em>n</em> = 111, low certainty evidence; SMD -0.25, 95 %CI -0.69 to 0.19, <em>p</em>-0.27, I²=0 %, 2 NSRIs pretest/post-test, <em>n</em> = 40, very low certainty evidence). No differences were found between <em>Bauhinia forficata</em> and <em>Imperata brasiliensis</em> (glycemia SMD -0.03, 95 % CI -1.01 to 0.95, <em>p</em> = 0.96, 1 RCT, <em>n</em> = 16, very low certainty evidence; HbA1c SMD 0.06, 95 % CI -0.92 to 1.04, <em>p</em> = 0.96, 1 RCT, <em>n</em> = 16, very low certainty evidence).</p></div><div><h3>Conclusions</h3><p>The findings suggest that <em>Bauhinia forficata</em> may be effective in reducing blood glucose levels; however, this evidence needs to be interpreted with caution.</p></div><div><h3>PROSPERO registration</h3><p>CRD42022370143.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"65 ","pages":"Article 102331"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139375003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of aromatherapy on anxiety in patients with cancer: A systematic review and meta-analysis of randomized controlled trials","authors":"Ju Hyun Ahn,&nbsp;Myoungsuk Kim","doi":"10.1016/j.eujim.2023.102323","DOIUrl":"10.1016/j.eujim.2023.102323","url":null,"abstract":"<div><h3>Introduction</h3><p>Patients with cancer often experience anxiety during cancer diagnosis and treatment, which can negatively impact their treatment outcomes. Although aromatherapy is believed to be effective in reducing anxiety in patients with cancer, the evidence has been limited. This review aimed to investigate the effectiveness of aromatherapy in reducing anxiety in patients with cancer and identify potential moderators of the intervention effects.</p></div><div><h3>Methods</h3><p>This review was conducted using data from PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), MEDLINE, Cochrane Library, and Web of Science, Regional Information Sharing Systems (RISS), Korean Information Service System (KISS), KoreaMed, and DBpia until March 16, 2023. The final analysis included 11 comparisons from 10 studies that administered aromatherapy to patients with cancer aged 18 years or older. The intervention effect was calculated by the standardized mean difference (SMD), and moderator analysis was performed using subgroup, meta-analysis of variance, and meta-regression analyses. The risk of bias was assessed using the revised Cochrane risk-of-bias tool for randomized trials.</p></div><div><h3>Results</h3><p>The overall impact of aromatherapy on anxiety reduction in patients with cancer indicated a large effect size (SMD = -0.97, 95 % confidence interval: -1.60 – -0.35, I² = 94 %). In the subgroup analysis, the types of delivery methods and duration of the intervention were not found to be moderators causing heterogeneity in the effect sizes between trials. However, it was confirmed that the types of essential oils moderated the effects (Qb = 7.80, df = 2, <em>p</em>_b = 0.020). Additionally, continuous moderators were not found to significantly moderate the intervention effect.</p></div><div><h3>Conclusion</h3><p>This review demonstrates that aromatherapy reduces anxiety in patients with cancer, suggesting the possibility of its application in clinical and community settings. However, considering the limited quantity of randomized controlled trials (RCTs) available for subgroup analysis, which potentially impacts the precision of study outcomes, further research is warranted by incorporating additional RCTs.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"65 ","pages":"Article 102323"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138683911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Naturopaths’ approach to care of women with infertility: A cross-sectional survey","authors":"Alison Maunder ,&nbsp;Susan Arentz ,&nbsp;Mike Armour ,&nbsp;Michael F Costello ,&nbsp;Carolyn Ee","doi":"10.1016/j.eujim.2023.102329","DOIUrl":"10.1016/j.eujim.2023.102329","url":null,"abstract":"<div><h3>Introduction</h3><p>Infertility affects approximately one in six couples of reproductive age. Many women use traditional, complementary and integrative medicine to improve their chances of conceiving. While there is evidence of the use of naturopathy by women attempting to conceive, there is no evidence of the way that naturopaths approach and manage their treatment. This study aims to describe how naturopaths manage female infertility, including their approaches, clinical decisions, knowledge sources, and safety considerations in providing naturopathic care.</p></div><div><h3>Methods</h3><p>Naturopaths in Australia or New Zealand, routinely treating female reproductive health concerns and practicing for at least two years were invited to complete an online survey through their professional naturopathic associations.</p></div><div><h3>Results</h3><p>Data from 45 respondents were included. Women seeking preconception health and fertility promotion were frequently seen by 53 % and 44 % of the naturopaths, respectively. The naturopaths’ clinical management approaches for infertility were wide-ranging and extended beyond fertility. They reported prioritising peer-reviewed journal articles in guiding clinical decisions, collaborating with health practitioners (mostly general practitioners) and reporting adverse events. Most naturopaths (95 %) utilised multiple treatment strategies, recommending dietary and lifestyle modifications and a combination of ingestible substances.</p></div><div><h3>Conclusions</h3><p>The naturopathic approach to management of women with infertility is holistic, considering physical, emotional, and environmental factors and promoting natural healing mechanisms. Greater knowledge of scientific methods for clinical decision-making and improved awareness of adverse event reporting would enhance naturopathic care. Additionally, evaluating the effectiveness of naturopathic treatment would improve safety, inform the profession, and clarify the role of naturopathy within a multidisciplinary approach to infertility.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"66 ","pages":"Article 102329"},"PeriodicalIF":2.5,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1876382023001051/pdfft?md5=e1b331864a74726d86746d4452c47937&pid=1-s2.0-S1876382023001051-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139031876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medical service utilization patterns among adults with insomnia: A retrospective cohort study","authors":"Min Kyung Hyun,&nbsp;Jang Won Lee","doi":"10.1016/j.eujim.2023.102325","DOIUrl":"10.1016/j.eujim.2023.102325","url":null,"abstract":"<div><h3>Introduction</h3><p>Patients with insomnia can use Korean medicine (KM) alongside conventional medicine (CM) as treatment options within the Korean healthcare system, but the treatment patterns for insomnia remain unclear. This study evaluated the incidence of newly diagnosed insomnia and medical service utilization, including untreated, CM, KM, and concurrent use of CM and KM, and the determinants of treatment after the insomnia diagnosis.</p></div><div><h3>Methods</h3><p>This retrospective cohort study analyzed adult Korean patients newly diagnosed with insomnia between 2016 and 2018 using National Health Insurance Service data. The cohort who met the eligibility criteria for insomnia was followed up until 2019 to identify their medical service utilization and the determinants. The medical service utilization was defined based on outpatient visits or hospitalization records with insomnia as the primary diagnosis. Descriptive statistics and logistic regression analysis were used to identify the medical service utilization and its determinants.</p></div><div><h3>Results</h3><p>Among the 336,578 patients newly diagnosed with insomnia in 2016–2018, only 155,538 (46.21 %) received more than two insomnia treatments during the follow-up period. Of these, 104,751 (67.35 %), 41,762 (26.85 %), and 9,025 (5.80 %) patients received CM monotherapy, KM alone, and both CM and KM, respectively. The statistically significant factors for receiving insomnia treatment after diagnosis were female, age ≥30 years, Seoul capital area residents, lowest income quintile, National Health Insurance Service (NHIS) enrollment types excluding the employee type, and longer elapsed time after diagnosis. The factors for receiving KM alone rather than CM alone were female, aged 40–79 years, residents of the Seoul capital area and metropolitan city, higher income, employee type among the NHIS enrollment types, and a more recent diagnosis. The common factor for concurrent use rather than CM alone was aged 40–79 years, and concurrent use rather than KM alone was being male.</p></div><div><h3>Conclusions</h3><p>More than half of the patients with insomnia received treatment only once. The utilization of CM or KM alone was higher than that of their combined use. Healthcare professionals can utilize these findings to manage patients with insomnia effectively.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"67 ","pages":"Article 102325"},"PeriodicalIF":2.5,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138684316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and safety of Simiao Xiaobi decoction on rheumatoid arthritis: A systematic review and meta‑analysis","authors":"Soo-Yeon Chae ,&nbsp;Seo-Hyun Park ,&nbsp;Joo-Hee Kim ,&nbsp;Eun-Jung Kim ,&nbsp;Byung-Kwan Seo ,&nbsp;Seong-Sik Park ,&nbsp;Won-Suk Sung","doi":"10.1016/j.eujim.2023.102322","DOIUrl":"10.1016/j.eujim.2023.102322","url":null,"abstract":"<div><h3>Introduction</h3><p>Simiao Xiaobi decoction (SXD) is a traditional Chinese medicine (TCM) formula that has been clinically applied for rheumatoid arthritis (RA). This meta-analysis aimed to systematically assess the therapeutic efficacy and safety of SXD compared to conventional therapy.</p></div><div><h3>Methods</h3><p>Twelve worldwide databases were searched for randomized controlled trials (RCTs) of treating RA with SXD and comparing non-operative conventional treatments (e.g., medication) from inception to August 2023. Primary outcomes for disease activity were effective rate (ER), joint pain score (JPS), joint swelling score (JSS), and morning stiffness (MS), and secondary outcome measures were laboratory inflammation markers and adverse events. The efficacy was presented as the risk ratio (RR) or mean difference (MD) with 95 % confidence interval (CI) using Review Manager. Risk of bias and the quality of evidence were assessed by using Cochrane “risk of bias” tool and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE).</p></div><div><h3>Results</h3><p>A total of 16 RCTs involving 1,749 patients were included. Compared with conventional treatments, SXD monotherapy significantly improved the ER (RR = 1.34, 95 % CI [1.26, 1.43], 14 RCTs, <em>n</em> = 1,578), JPS (MD = -1.00, 95 % CI [–1.33, –0.68], 4 RCTs, <em>n</em> = 327), JSS (MD = -1.59, 95 % CI [–2.12, –1.05], 4 RCTs, <em>n</em> = 327), MS (MD = -0.39, 95 % CI [–0.59, –0.18], 6 RCTs, <em>n</em> = 525), and laboratory results, and SXD add-on therapy significantly improved the ER (RR = 1.22, 95 % CI [1.00, 1.49], 1 RCT, <em>n</em> = 70). Due to some concerns with risk of bias, small sample sizes, and/or inconsistency, the certainty of evidence for SXD monotherapy was moderate for ER, low for JPS and JSS, very low for MS, and very low for SXD add-on therapy. There were fewer cases of adverse events in the SXD group.</p></div><div><h3>Conclusion</h3><p>Our findings suggest that SXD can be a complementary treatment option. However, the methodological quality of the included RCTs was unsatisfactory, so further high-quality research is needed to confirm our results.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"65 ","pages":"Article 102322"},"PeriodicalIF":2.5,"publicationDate":"2023-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1876382023000987/pdfft?md5=92fcece4b08012fa089387c87e67442e&pid=1-s2.0-S1876382023000987-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138508570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Naturopaths’ approach to care of women with infertility: a cross-sectional survey","authors":"Alison Maunder, S. Arentz, Mike Armour, Michael F Costello, Carolyn Ee","doi":"10.1016/j.eujim.2023.102329","DOIUrl":"https://doi.org/10.1016/j.eujim.2023.102329","url":null,"abstract":"","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"815 ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139018630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical efficacy and safety of Shensong Yangxin capsule-antiarrhythmic drug combination for paroxysmal atrial fibrillation: A meta-analysis of randomized controlled trials","authors":"Xinfu Cao ,&nbsp;Zhenhua Gu ,&nbsp;Yi Sun ,&nbsp;Yuqiao Chen ,&nbsp;Chao Tang ,&nbsp;Hongwen Yu ,&nbsp;Xiaolong Li","doi":"10.1016/j.eujim.2023.102320","DOIUrl":"10.1016/j.eujim.2023.102320","url":null,"abstract":"<div><h3>Introduction</h3><p>Shensong Yangxin Capsule (SSYX) is a famous traditional Chinese patent medicine produced in China for the treatment of arrhythmia. Recently, China released a series of randomized controlled trials (RCTs) using SSYX combined with antiarrhythmic drugs (ADs) for the treatment of paroxysmal atrial fibrillation (PAF). However, these RCTs have not been systematically evaluated. The purpose of this review was to assess the effectiveness and safety of SSYX combined with AD (SSYX-AD) in the treatment of PAF.</p></div><div><h3>Methods</h3><p>RCTs of SSYX-AD in the treatment of PAF were collected by searching the Chinese Knowledge Infrastructure Database (CNKI), PubMed, Chinese Scientific Journal Database (VIP), Wanfang Database, Cochrane Library, China Biomedical Database Network (CBM), Excerpt Medica Database (EMBASE), and clinical trial platforms such as the UK National Research Registry (NRR), the World Health Organization Clinical Trial Registry (ICTRP), and the Chinese Clinical Trial Registry (CCTR) from its creation until July 1, 2023. The primary outcome was the effective rate. The secondary outcomes were the frequency of atrial fibrillation (FAF), left atrial diameter (LAD), P wave dispersion (PWD), adverse reactions (ADRs), left ventricular ejection fraction (LVEF), and sinus rhythm maintenance rate (SRMR). The quality assessment of RCTs was completed using the Cochrane risk-of-bias tool, and the meta-analysis was completed using RevMan 5.3 software. This review was conducted in accordance with the PROSPERO-registered protocol (number: CRD42023413442).</p></div><div><h3>Results</h3><p>The review included a total of 29 RCTs including 2766 patients. The review showed that the SSYX-AD group had more advantages than AD group in improving the effective rate [RR=1.18; 95 % CI (1.12, 1.24); <em>p</em> &lt; 0.01], LVEF [MD =3.40; 95 % CI (0.91, 5.88); <em>p</em> = 0.007], SRMA [RR=1.38; 95 % CI (1.22, 1.57); <em>p</em> &lt; 0.01], and was superior to AD alone in reducing the FAF [MD=2.89; 95 % CI (1.57, 4.21); <em>p</em> &lt; 0.01], LAD [MD=2.44; 95 % CI (0.85, 4.03); <em>p</em> &lt; 0.01], PWD [MD = 4.90; 95 % CI (2.81, 6.99); <em>p</em> &lt; 0.05], and ADRs [RR=0.41; 95 % CI (0.29, 0.58); <em>p</em> &lt; 0.01].</p></div><div><h3>Conclusions</h3><p>Despite the apparently positive outcomes presented, due to the low methodological quality of the included RCTs there was insufficient evidence to recommend routine use of SSYX-AD for PAF. The aggregate effect must be validated by additional well-designed, adequately sampled, and methodologically sound clinical studies.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"65 ","pages":"Article 102320"},"PeriodicalIF":2.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138508568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of Shengmai injection for chronic cor pulmonale: A systematic review with meta-analysis and trial sequential analysis of 31 randomized controlled trials","authors":"Xunxun Yuan ,&nbsp;Xianjie Feng ,&nbsp;Jun He ,&nbsp;Sheng Xu ,&nbsp;Xu Zhou ,&nbsp;Lihua Wang","doi":"10.1016/j.eujim.2023.102318","DOIUrl":"10.1016/j.eujim.2023.102318","url":null,"abstract":"<div><h3>Introduction</h3><p>This study aimed to systematically evaluate the efficacy and safety of Shengmai injection (<em>Radix ginseng, Radix ophiopogonis,</em> and <em>Fructus Schisandrae chinensis</em>) as an adjunct to conventional medicine in the treatment of chronic cor pulmonale.</p></div><div><h3>Methods</h3><p>A search of ten databases was conducted up to March 27, 2023, to identify randomized controlled trials that assessed the efficacy of Shengmai injection plus conventional medicine versus conventional medicine alone in the treatment of chronic cor pulmonale. Meta-analysis was performed using RevMan version 5.4, with risk ratios (RRs), mean differences (MDs), and 95 % confidence intervals (CIs) used as effect measures. Trial sequential analyses were conducted to quantify the statistical reliability of the data in the studies.</p></div><div><h3>Results</h3><p>A total of 31 studies involving 3,036 patients were included in the meta-analysis. The results showed that Shengmai injection combined with conventional therapies significantly improved the response to treatment (RR 1.24, CIs 1.19 to 1.29) as well as heart function (e.g., left ventricular ejection fraction: MD 8.14 % [CIs 2.33 to 13.95]; right ventricular ejection fraction: MD 8.51 % [CIs 3.61 to 13.41], stroke volume: MD 12.38 mL [CIs 4.80 to 19.96], cardiac output: MD 0.35 L/min, [CIs 0.19 to 0.50], cardiac index: MD 0.45 L/min·m², [CIs 0.19 to 0.72]), blood gas indicators (SaO₂: MD 4.18 % [CIs 3.12 to 5.25], PaO₂: MD 5.63 mmHg [CIs 4.26 to 7.00]), and lung function (FEV₁: MD 0.40 L [CIs 0.26 to 0.53], FEV₁/FVC: MD 10.10 % [CIs 7.43 to 12.77]) in patients with cor pulmonale. Additionally, no significant improvement was observed in creatine kinase isoenzyme- myocardial band or plasma viscosity compared with the controls. Two cases (4 %) of mild adverse events (dry mouth) possibly related to Shengmai injection were reported, but no serious adverse events were observed.</p></div><div><h3>Conclusions</h3><p>Shengmai injection may be an effective supplemental therapy for chronic cor pulmonale, potentially improving treatment response, heart and lung functioning, blood gas analysis, and hemorheological indicators, with an acceptable safety profile. However, the risk of selection bias and high heterogeneity in some studies highlight the need for further multicenter, large-sample randomized controlled trials to validate these findings.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"65 ","pages":"Article 102318"},"PeriodicalIF":2.5,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S187638202300094X/pdfft?md5=a2a653895ad67f5c3f56c0a2df40b625&pid=1-s2.0-S187638202300094X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138508571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}